Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Cancer letters - 1 Dec 2018

Wang Shan, Ekoue Dede N, Raj Ganesh V, Kittler Ralf

Abstract excerpt

The current therapeutic armamentarium for castration-resistant prostate cancer (CRPC) includes second-generation agents such as the Androgen Receptor (AR) inhibitor enzalutamide and the androgen synthesis inhibitor abiraterone acetate, immunotherapies like sipuleucel-T, chemotherapies including docetaxel and cabazitaxel and the radiopharmaceutical radium 223 dichloride. However, relapse of CRPC resistant to these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Oncogene Proteins

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 30217566
DOI: 10.1016/j.canlet.2018.09.010
PMCID: PMC6186492

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.PMID 30217566Read ↗

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

Persistent androgen receptor addiction in castration-resistant prostate cancerSemantic proximity Read ↗

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistanceSemantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate CancerSemantic proximity Read ↗

Progress in the mechanism and drug development of castration-resistant prostate cancer.Semantic proximity Read ↗

Targeting extra-gonadal androgens in castration-resistant prostate cancer.Semantic proximity Read ↗

Constitutive activity of the androgen receptor.Semantic proximity Read ↗

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.Semantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

[Current status of castration resistant prostate cancer basic research].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.